Uncategorized
Kala’s KPI-121 resolves inflammation, pain after cataract surgery in phase 3 trial
Kala Pharmaceuticals released positive topline results from a phase 3 trial of KPI-121 for the treatment of pain and inflammation in patients who underwent cataract surgery, according to a press release.All primary efficacy endpoints were achieved, KPI-121 was well tolerated, and there were no treatment-related safety issues during the trial, the release said.